001     286699
005     20241217142807.0
024 7 _ |a 10.1007/s10654-023-01059-4
|2 doi
024 7 _ |a pmid:38180593
|2 pmid
024 7 _ |a 0393-2990
|2 ISSN
024 7 _ |a 1573-7284
|2 ISSN
024 7 _ |a altmetric:158140475
|2 altmetric
037 _ _ |a DKFZ-2024-00039
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Botteri, Edoardo
|0 0000-0002-9023-8068
|b 0
245 _ _ |a Lifestyle changes in middle age and risk of cancer: evidence from the European Prospective Investigation into Cancer and Nutrition.
260 _ _ |a Dordrecht [u.a.]
|c 2024
|b Springer Science + Business Media B.V.
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1713784777_12989
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a 2024 Feb;39(2):147-159
520 _ _ |a In this study, we aimed to provide novel evidence on the impact of changing lifestyle habits on cancer risk. In the EPIC cohort, 295,865 middle-aged participants returned a lifestyle questionnaire at baseline and during follow-up. At both timepoints, we calculated a healthy lifestyle index (HLI) score based on cigarette smoking, alcohol consumption, body mass index and physical activity. HLI ranged from 0 (most unfavourable) to 16 (most favourable). We estimated the association between HLI change and risk of lifestyle-related cancers-including cancer of the breast, lung, colorectum, stomach, liver, cervix, oesophagus, bladder, and others-using Cox regression models. We reported hazard ratios (HR) with 95% confidence intervals (CI). Median time between the two questionnaires was 5.7 years, median age at follow-up questionnaire was 59 years. After the follow-up questionnaire, we observed 14,933 lifestyle-related cancers over a median follow-up of 7.8 years. Each unit increase in the HLI score was associated with 4% lower risk of lifestyle-related cancers (HR 0.96; 95%CI 0.95-0.97). Among participants in the top HLI third at baseline (HLI > 11), those in the bottom third at follow-up (HLI ≤ 9) had 21% higher risk of lifestyle-related cancers (HR 1.21; 95%CI 1.07-1.37) than those remaining in the top third. Among participants in the bottom HLI third at baseline, those in the top third at follow-up had 25% lower risk of lifestyle-related cancers (HR 0.75; 95%CI 0.65-0.86) than those remaining in the bottom third. These results indicate that lifestyle changes in middle age may have a significant impact on cancer risk.
536 _ _ |a 313 - Krebsrisikofaktoren und Prävention (POF4-313)
|0 G:(DE-HGF)POF4-313
|c POF4-313
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
650 _ 7 |a Cancer risk
|2 Other
650 _ 7 |a Cohort study
|2 Other
650 _ 7 |a Healthy lifestyle index
|2 Other
650 _ 7 |a Lifestyle changes
|2 Other
700 1 _ |a Peveri, Giulia
|b 1
700 1 _ |a Berstad, Paula
|b 2
700 1 _ |a Bagnardi, Vincenzo
|b 3
700 1 _ |a Hoff, Geir
|b 4
700 1 _ |a Heath, Alicia K
|b 5
700 1 _ |a Cross, Amanda J
|b 6
700 1 _ |a Vineis, Paolo
|b 7
700 1 _ |a Dossus, Laure
|b 8
700 1 _ |a Johansson, Mattias
|b 9
700 1 _ |a Freisling, Heinz
|b 10
700 1 _ |a Matta, Komodo
|b 11
700 1 _ |a Huybrechts, Inge
|b 12
700 1 _ |a Chen, Sairah L F
|b 13
700 1 _ |a B Borch, Kristin
|b 14
700 1 _ |a Sandanger, Torkjel M
|b 15
700 1 _ |a H Nøst, Therese
|b 16
700 1 _ |a Dahm, Christina C
|b 17
700 1 _ |a Antoniussen, Christian S
|b 18
700 1 _ |a Tin Tin, Sandar
|b 19
700 1 _ |a Fournier, Agnès
|b 20
700 1 _ |a Marques, Chloé
|b 21
700 1 _ |a Artaud, Fanny
|b 22
700 1 _ |a Sánchez, Maria-José
|b 23
700 1 _ |a Guevara, Marcela
|b 24
700 1 _ |a Santiuste, Carmen
|b 25
700 1 _ |a Agudo, Antonio
|b 26
700 1 _ |a Bajracharya, Rashmita
|0 P:(DE-He78)0b48ce513fe49013263657450a12f870
|b 27
|u dkfz
700 1 _ |a Katzke, Verena
|0 P:(DE-He78)fb68a9386399d72d84f7f34cfc6048b4
|b 28
|u dkfz
700 1 _ |a Ricceri, Fulvio
|b 29
700 1 _ |a Agnoli, Claudia
|b 30
700 1 _ |a Bergmann, Manuela M
|b 31
700 1 _ |a Schulze, Matthias B
|b 32
700 1 _ |a Panico, Salvatore
|b 33
700 1 _ |a Masala, Giovanna
|b 34
700 1 _ |a Tjønneland, Anne
|b 35
700 1 _ |a Olsen, Anja
|b 36
700 1 _ |a Stocks, Tanja
|b 37
700 1 _ |a Manjer, Jonas
|b 38
700 1 _ |a Aizpurua-Atxega, Amaia
|b 39
700 1 _ |a Weiderpass, Elisabete
|b 40
700 1 _ |a Riboli, Elio
|b 41
700 1 _ |a Gunter, Marc J
|b 42
700 1 _ |a Ferrari, Pietro
|b 43
773 _ _ |a 10.1007/s10654-023-01059-4
|0 PERI:(DE-600)2004992-4
|n 2
|p 147-159
|t European journal of epidemiology
|v 39
|y 2024
|x 0393-2990
856 4 _ |u https://inrepo02.dkfz.de/record/286699/files/s10654-023-01059-4.pdf
856 4 _ |u https://inrepo02.dkfz.de/record/286699/files/s10654-023-01059-4.pdf?subformat=pdfa
|x pdfa
909 C O |p VDB
|o oai:inrepo02.dkfz.de:286699
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 27
|6 P:(DE-He78)0b48ce513fe49013263657450a12f870
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 28
|6 P:(DE-He78)fb68a9386399d72d84f7f34cfc6048b4
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-313
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Krebsrisikofaktoren und Prävention
|x 0
914 1 _ |y 2024
915 _ _ |a National-Konsortium
|0 StatID:(DE-HGF)0430
|2 StatID
|d 2023-08-25
|w ger
915 _ _ |a DEAL Springer
|0 StatID:(DE-HGF)3002
|2 StatID
|d 2023-08-25
|w ger
915 _ _ |a DEAL Springer
|0 StatID:(DE-HGF)3002
|2 StatID
|d 2023-08-25
|w ger
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b EUR J EPIDEMIOL : 2022
|d 2023-08-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2023-08-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2023-08-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2023-08-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2023-08-25
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2023-08-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2023-08-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2023-08-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2023-08-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2023-08-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2023-08-25
915 _ _ |a IF >= 10
|0 StatID:(DE-HGF)9910
|2 StatID
|b EUR J EPIDEMIOL : 2022
|d 2023-08-25
920 1 _ |0 I:(DE-He78)C020-20160331
|k C020
|l C020 Epidemiologie von Krebs
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)C020-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21